TNFRSF9 and Splenomegaly: A similar study involving treatment of B6.lpr or MRLlpr lupus-prone mice with agonistic anti-CD137 antibody (clone 2A) i.p. for three weekly doses commencing at the age of 2–3 months produced similar results in terms of improvement of survival, reduced severity of cutaneous inflammation, splenomegaly, lymphadenopathy and lupus glomerulonephritis and a reduction in serum anti-dsDNA IgG levels compared to mice of the same strain receiving control rat IgG [33].